BioPharma Resources

Drug Trial Radar · NCT05727397

Efficacy and Safety of RC28-E Versus Aflibercept

A Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RC28-E 2mg Versus Aflibercept in Subjects With Wet Age-Related Macular Degeneration

Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 432 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

432

Planned (sponsor's estimate)

Start

Mar 14, 2023

Primary completion

Nov 29, 2025

Study completion Dec 29, 2025

Sponsor

Lead sponsor
RemeGen Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.

Conditions

  • Wet Age-related Macular Degeneration

Interventions

  • RC28-EDrug

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

  • AfliberceptDrug

    Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 µL dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in BCVA at week 48;Time frame: Baseline, week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.